Introduction
Staphylococcus aureus (S. aureus) is the leading cause of life-threatening endovascular infections [1] . One of the most feared complications of invasive S. aureus disease is infective endocarditis. Compared with other pathogens, infective endocarditis caused by S. aureus has a higher mortality and is more frequently associated with severe complications [2, 3] .
Once S. aureus infects the heart valves, almost one in three patients will die, despite aggressive surgery and antibiotics [4] . The dramatic morbidity and mortality of S. aureus endocarditis have remained unchanged over the past decades. This stresses the need for new therapeutic strategies to prevent and treat infective endocarditis.
To cause endocarditis, bacteria first need to adhere to the endothelium of the heart valve. However, binding to endothelial cells in flowing blood requires mechanisms to withstand shear stress. A better understanding of the initial binding of S. aureus to the valvular endocardium will allow the development of new strategies to prevent and treat endocarditis.
We and others showed that S. aureus adheres to the vessel wall under flow by binding to von Willebrand factor (VWF) [5, 6] . VWF binds to sites of vascular damage and is exposed on the endothelial surface upon activation or injury [7] . VWF multimers are cleaved by ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) [8] . The binding of S. aureus to VWF is mediated by the von Willebrand factor-binding protein (vWbp); however, because vWbp is thought to be a secreted protein not anchoring to the cell wall, it remains unclear how vWbp mediates bacterial attachment.
S. aureus expresses a number of bacterial cell wallanchored surface proteins that mediate bacterial adherence to host cells and to extracellular matrix components. Several of these S. aureus surface proteins, or MSCRAMMs (microbial surface components recognizing adhesive matrix molecules), have been proposed to contribute to the pathogenesis of endovascular infections [9] [10] [11] . Many of those MSCRAMMs, which recognize fibronectin, fibrinogen, collagen or VWF, have a conserved C-terminal cell wall sorting signal with a LeuPro-X-Thr-Gly (LPXTG) motif [12] . Together, more than 20 members of this family of cell wall-anchored surface proteins have been identified in the S. aureus genome [13] [14] [15] . This sorting signal triggers the covalent anchoring of these proteins to the bacterial cell wall by Sortase A (SrtA), a transpeptidase [12] . Strains with a mutation in the srtA gene lack these cell wall-anchored proteins [14] .
We hypothesized that vWbp bridges VWF with a cell wall-anchored surface protein of S. aureus. In this study we identify the bacterial binding partners for vWbp and unravel the mechanism of S. aureus binding to the vascular wall under shear stress, a crucial step in the early phases of the infectious process.
Materials and methods

Bacterial strains
S. aureus strains were stored in Brain Heart Infusion with 10% glycerol at À80°C. Bacteria were grown overnight in tryptic soy broth at 37°C. The reference strain used in this study is S. aureus Newman [16] . Isogenic single mutants of S. aureus Newman [17] [18] [19] are listed in Table 1 . Lactococcus lactis (L. lactis) strains [11, 20] were grown overnight at 37°C in M17 medium (Fluka, Sigma-Aldrich, Darmstadt, Germany) supplemented with 0.5% glucose and 5 lg mL À1 erythromycin and stored in M17 medium supplemented with 10% glycerol at À80°C. The strains used in this study are listed in Table 1 . Escherichia coli (E. coli) strains DH5a and BL21 (DE3) were cultured on Luria agar or broth at 37°C. Ampicillin (100 lg mL
À1
) and erythromycin (10 lg mL
) were used for plasmid selection.
Expression and purification of proteins
Recombinant His 6 -vWbp (rvWbp) without the signal sequence and lacking coagulase activity was cloned with plasmid pET15 and was purified from E. coli BL21 (DE3) using Ni-trilotriacetic acid (Ni-NTA) chromatography as previously described [21] . Recombinant vWbp-Strep was cloned with pET22b and was purified from E. coli BL21 (DE3) using Strep-Tactin affinity chromatography as previously described [22] . Recombinant His 6 -ClfA 1-520 was (ClfA, Clumping factor A) cloned with plasmid pET15 and [20] purified from E. coli BL21 (DE3) using Ni-NTA chromatography as previously described [23] . Glutathione-Stransferase (GST)-VWF A1-domain proteins were produced as described before [24] .
Cell wall and secreted protein extraction S. aureus Newman (wild-type) and coa/vwb deletion mutant (Table 1) 
Western blot analysis
Cell wall and secreted proteins were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes in a Trans-Blot Turbo apparatus (Bio-Rad, Nazareth, Belgium). Membranes were incubated overnight with a house-made polyclonal antibody against rvWbp (1:500). After adding horseradish peroxidase-conjugated secondary antibodies, immunoreactive bands were visualized by Enhanced chemiluminescence (Amersham Biosciences, Diegem, Belgium).
In vitro perfusion experiments
In vitro perfusion experiments were performed as previously described [6, 25] . Glass coverslips (24 9 50 mm, VWR International, Leuven, Belgium) were coated with 50 lg mL ), rvWbp or bacterial supernatant added to the perfusate. Membranebound rvWbp was prepared by supplementing vwb (S. aureus strain lacking vWbp) with rvWbp and after an incubation period of 15 min, unbound rvWbp was removed by centrifugation. Bacterial supernatant was prepared by incubating washed bacteria for 4 h at 37°C in PBS. Bacteria were then removed by centrifugation and filtering (Millex Filter Unit 0.22 lm, Merck Millipore). Live images were obtained using an inverted fluorescence microscope and video microscopy as reported [6] . Images were digitally stored and fluorescence was measured with ImageJ analysis software (National Institutes of Health, Bethesda, MD, USA). The intensity of fluorescence is reported as relative bacterial adhesion.
Bacterial adhesion to endothelial cells
Human umbilical vein endothelial cells (HUVECs) were isolated from fresh umbilical cords of healthy donors as described before [6, 25] . HUVECs were seeded on 1% gelatin-coated (Sigma-Alderich) plastic coverslips (Sarstedt, N€ umbrecht, Germany) and grown to confluence. The coverslips were mounted in a micro-parallel flow chamber and the HUVECs were activated with 0.1 mM Ca 2+ -ionophore A23187 (Sigma-Aldrich) for 10 min and perfused for 10 min with fluorescently labeled bacteria (OD 600 of 1.2). Where indicated, 20 lg mL À1 rvWbp, 2.5 lg mL À1 rADAMTS-13 and/or 10 lg mL À1 anti-VWF A1 domain antibody were added to the bacterial perfusate. Bacterial adhesion was recorded as described above.
In vivo mesenteric perfusion model
Six-to eight-week-old C57Bl/6 mice were anesthetized with ketamine/xylazine and their right jugular veins were catheterized (Portex intravenous cannula, 2F). The peritoneal cavity was opened via midline abdominal incision and the mesenteric microcirculation was visualized with an inverted microscope (Axio-observer D1, Carl-Zeiss NV, Zaventem, Belgium). To activate the endothelium and cause VWF release, 5 lL of the Ca 2+ -ionophore A23187 (10 mM) was locally applied to the vascular bed. Subsequently, 100 lL of a suspension of fluorescently labeled bacteria (final concentration of 60 lg mL À1 carboxy-fluorescein and an OD 600 of 1.8, corresponding to approximately 1 9 10 9 CFU mL
À1
) was injected through the catheter. Where indicated, 20 lg mL À1 of rvWbp was added to the bacterial inoculum. Live time-lapse images (1 image per second, 40 images) were acquired with an inverted fluorescence microscope, captured via a black and white camera and developed using image software. The fluorescent signal in the blood vessel was quantified manually for each frame and reported as described above. Animal experiments were approved by the Ethical Committee of the University of Leuven (P110/2014). For immunofluorescence staining, the blood vessels were dissected and fixed with paraformaldehyde 4% overnight and imbedded in parafine. A polyclonal anti-VWF rabbit antibody (31 lg mL À1 ) (Dako, Glostrup, Denmark) was used as primary antibody and a goat anti-rabbit Alexa Fluor-568 (20 lg mL
) (Invitrogen, Carlsbad, CA, USA) as secondary antibody. Endothelial cells were counterstained with 4',6-diamidino-2-phenylindole.
Surface plasmon resonance
Affinity and rates of association were measured on a BIAcore 3000 (GE Healthcare, Hillerod, Denmark). Buffers were sterile filtered and degassed. A nitrilotriacetic acid (NTA) chip (GE Healthcare, Diegem, Belgium) was used to capture histidine-tagged [27] ligands. The NTA chip was prepared for ligand capturing by injecting NiCl 2 (0.5 M) (GE Healthcare, Diegem, Belgium) followed by injection of 20 lL His-ClfA 1-520 (200 nM). His-ClfA 1-520 and vWbpStrep were diluted in running buffer (HBS-P buffer (20 mM HEPES [pH 7.4], 150 mM NaCl, 0.005% [vol/vol] surfactant P20) (GE Healthcare, Diegem, Belgium), 50 uM ethylenediaminetetraacetic acid (EDTA) (GE Healthcare, Diegem, Belgium) and 1 mM imidazole). To study the HisClfA 1-520 -vWbp interaction, vWbp-Strep was injected at 6.25 nM, 12.5 nM and 25 nM for 180 s, followed by regeneration of the chip with 50 lM EDTA and 1 mM imidazole. All injections were performed at a flow rate of 10 lL min À1 .
Kinetic coefficients, K A and K D , were determined using the BiaEvaluation software (GE Healthcare, Diegem, Belgium) and best fit was determined with a 1 : 1 binding model with drifting baseline and local R max . All experiments were repeated in triplicate on at least three occasions.
Statistical analysis
All calculations were carried out with GraphPad Prism 5.0d (GraphPad Software, San Diego, CA USA). Groups were compared with the one-way ANOVA or a two-tailed Student's t-test. All values are reported as mean AE standard error of the mean (SEM). A P-value of < 0.05 was considered significant (*P < 0.05; **P < 0.01; ***P < 0.001).
Results
Secreted vWbp interacts with both VWF and the S. aureus cell wall
We previously described that the shear-dependent adhesion of S. aureus to endothelial cells and subendothelial matrix is mediated by complex formation between VWF and staphylococcal vWbp [6] . To promote bacterial adhesion, secreted vWbp has to be able to interact with the S. aureus cell wall. Western blotting confirmed that vWbp is secreted by the S. aureus Newman wild-type strain (WT), but it was also found attached to the cell wall (Fig. 1A ). An S. aureus mutant strain lacking vWbp lacked both secreted and cell wall-bound vWbp. Added exogenous rvWbp was able to bind to the cell wall of the mutant strain lacking vWbp.
Compared with WT, perfusion of vwb over VWF resulted in reduced adhesion. Normal adhesion could be restored by either exogenous rvWbp (Fig. 1B) or by adding supernatant of the WT strain (Fig. 1C) , but not by adding supernatant of the vwb strain. Exogenous vWbp (rvWbp or vWbp present in WT supernatant) (Fig. 1B,  C) led to a 2-fold increase in the adhesion of vwb to VWF under flow (P = 0.021 and P = 0.048, respectively), indicating that vWbp interacts with S. aureus regardless of its ability to secrete vWbp.
This increase in adhesion was seen both when vwb was pre-incubated with rvWbp and when rvWbp was pre-perfused over VWF (Fig. 1D ) (P = 0.0003 and P = 0.003, respectively).
These findings show that vWbp is a secreted protein capable of both binding to VWF under flow and sticking to S. aureus, thereby promoting the adhesion of S. aureus to the vessel wall under flow via a ternary interaction.
vWbp binds to S. aureus via an SrtA-dependent surface protein
We hypothesized that S. aureus interacts with vWbp via a staphylococcal cell wall-anchored surface protein processed by SrtA.
In contrast to WT, the srtA strain (deficient in SrtA, which lacks all sortase A-dependent cell wall-anchored proteins) was not able to adhere to coated rvWbp ( Fig. 2A) (P < 0.0001). Binding of vwb to the rvWbp coating was similar to that of the WT strain (P = 0.56).
Pre-perfusion of coated VWF with rvWbp increased the adhesion of vwb but had no effect on the adhesion of srtA (Fig. 2B ) (P = 0.10), strengthening our interpretation that vWbp interacts with S. aureus through a sortase Adependent cell wall-anchored protein.
vWbp forms a complex with VWF and ClfA, promoting bacterial adhesion to endothelial cells and subendothelial matrix
To identify which SrtA-dependent protein is crucial for vWbp binding, we screened a set of mutants deficient in one single SrtA-dependent cell wall-anchored surface protein for their adhesiveness to coated rvWbp under flow. When compared with the WT strain, two SrtA-dependent cell wall-anchored surface protein deletion mutants showed decreased adhesion to rvWbp (i.e. the mutant lacking Clumping factor A [clfA] and the mutant lacking staphylococcal protein A) [28] (Fig. 3A) (P = 0.0001 and P = 0.0092, respectively).
We further assessed the adhesion profile of srtA, clfA and spa to VWF (Fig. 3B) . Compared with the WT strain, absence of SrtA and ClfA reduced adhesion by more than 75% (P = 0.0066 and P = 0.0066, respectively), whereas absence of SpA did not significantly reduce bacterial adhesion (P = 0.48).
Similarly, when compared with WT, srtA and clfA were unable to bind to collagen, the main component of the subendothelial matrix, regardless of the presence of VWF in the perfusate ( Figure SI) (P = 0.0009 and P = 0.0069, respectively). The adhesion of spa to collagen in the presence of VWF was similar to that of WT (P = 0.49), suggesting that ClfA is the main bacterial surface binding partner for vWbp mediating S. aureus adhesion to VWF under flow.
Exogenous rvWbp increased the adhesion of vwb to VWF under flow; however, different concentrations of rvWbp did not affect the adhesion of clfA to VWF ( Figure S2 ).
To validate whether this mechanism is capable of explaining bacterial adhesion to the endothelium, we examined the adhesion of WT, vwb, srtA, clfA and spa to resting and stimulated endothelial cells under flow.
Activation of endothelial cells facilitated the adhesion of the WT strain (Fig. 3C,D) . In contrast, in the absence of vWbp, SrtA or ClfA, S. aureus was no longer able to bind to the VWF-strings and bacterial adhesion was low even to stimulated endothelial cells (Fig. 3C ) (P = 0.0087, P = 0.0053 and P = 0.0077, respectively). However, addition of rvWbp increased the adhesion of vwb comparable to WT. Cleavage of VWF multimers by rADAMTS-13 decreased the adhesion of the WT strain by 60% (P = 0.0085) and combining rADAMTS-13 with an anti-VWF A1 domain antibody further decreased the WT adhesion to 10% (P = 0.0007) (Fig. 3E) .
These data identify ClfA as a crucial factor in the VWF-mediated binding of S. aureus to endothelial cells in flow conditions by acting as a bacterial binding partner for vWbp.
vWbp forms a complex with the VWF A1-domain and ClfA
Presence of isolated VWF A1-domain on the coverslip was sufficient to trigger adhesion of the WT strain, but not of vwb, srtA and clfA, suggesting that vWbp binds to the A1-portion of VWF (Fig. 4A ) (P = 0.0072, P = 0.0013 and P = 0.0045, respectively). This finding further provides an explanation for the previously recognized role of the VWF A1-domain in S. aureus binding to VWF [6] . To extend the submolecular localization of vWbp binding to the VWF A1-domain to interactions with ClfA, we measured the association of His-ClfA 1-520 with vWbpStrep by surface plasmon resonance (Fig. 4B) . Using a range of concentrations, we calculated the dissociation constant (K D ) to be around 1 nM for the interaction between soluble vWbp-Strep and immobilized His-ClfA 1-520 , representative of a moderately high affinity (Fig. 4B) .
These findings confirmed that vWbp interacts with the VWF A1-domain and with the S. aureus surface protein ClfA simultaneously.
L. lactis expressing staphylococcal ClfA binds to vWbp and to VWF in the presence of vWbp
We independently verified our findings using Lactococcus lactis (L. lactis) bacteria expressing single staphylococcal surface molecules on their cell walls. The control L. lactis pIL253 strain showed only minimal adhesion to rvWbp under flow. Expression of ClfA in L. lactis sufficed to allow adhesion to rvWbp under flow (Fig. 5A ) (P = 0.0018). L. lactis expressing FnBPA (Fibronectin binding protein A) or FnBPB (Fibronectin binding protein B), two well-described staphylococcal SrtA-dependent surface proteins, was unable to adhere to rvWbp. No adhesion of the L. lactis strains was observed to coated VWF A1-domain. However, when rvWbp was present, L. lactis expressing ClfA showed a significantly increased adhesion to the VWF A1-domain under flow (Fig. 5B) (P = 0.0354). rvWbp had no effect on the adhesion of L. lactis pIL253 or the lactococci expressing FnBPA or FnBPB (data not shown). Next, we examined the adhesion of L. lactis to endothelial cells under flow. L. lactis expressing ClfA was not able to adhere to activated endothelial cells. Adding rvWbp to the perfusate remarkably increased adhesion of this strain to activated endothelial cells under flow ( Together, these data show that expression of ClfA is sufficient to bind to the VWF A1-domain, but only in the presence of vWbp.
Adhesion of S. aureus to the vessel wall in vivo is mediated by the VWF-vWbp-ClfA complex
We confirmed these findings using an in vivo intravital mesenteric perfusion model. The WT strain was able to roll over and adhere to the activated murine vessel wall (Fig. 6A/B , Video S1) at the site of locally stimulated VWF release. Similar to our previous observations, the absence of ClfA or vWbp mitigated bacterial adhesion to the vessel wall compared with the WT strain (P = 0.0033 and P = 0.0050, respectively). However, supplementing vwb with rvWbp restored its adhesion to the vessel wall (P = 0.0005) (Video S2 and S3).
We conclude that vWbp interacts both with sheared VWF and with the staphylococcal surface protein ClfA. The ternary complex formed by endothelial VWF, secreted vWbp and bacterial ClfA mediates adhesion of S. aureus to the vascular endothelium with a high efficiency.
Discussion
Despite improvement in medical supportive care and the implementation of a more aggressive surgical approach, S. aureus infective endocarditis continues to have a very high mortality [29] . Furthermore, antibiotic resistance spreads at an alarming pace, urging new ways to prevent and treat this severe disease. The inability to improve outcome once infective endocarditis has been diagnosed underlines the importance of intervening at the early stages of the disease, preferably to prevent infective endocarditis from developing in the first place. Patients with S. aureus bacteremia are at high risk of developing infective endocarditis [30] . Infection of cardiac valves requires the binding of S. aureus to the endothelium under the high shear stress of flowing blood. Identifying virulence factors that mediate this initial binding can help to develop strategies to prevent infective endocarditis.
In our previous work we showed that S. aureus exploits the VWF-mediated binding that localizes platelets to sites of vascular damage or inflammation [6] . Although we rADAMTS-13 and/or 10 lg mL À1 anti-VWF A1 domain antibody were added to the perfusate (n ≥ 6). All results are expressed as mean AE SEM. *P < 0.05, **P < 0.01, ***P < 0.001. vWbp, von Willebrand factor-binding protein; VWF, von Willebrand factor; ClfA, Clumping factor A; rvWbp, recombinant His 6 -vWbp; WT, wild type; HUVECs, human umbilical vein endothelial cells.
identified the bacterial protein vWbp as a crucial factor, the precise mechanisms remained unclear, because vWbp is a secreted protein that lacks a cell-wall anchoring sequence.
In this study, we unravel how vWbp, a secreted protein, can bind to the bacterial cell wall, thus allowing shear-resistant binding of S. aureus to the inflamed or damaged endothelium and to the subendothelial matrix. We identified ClfA, an SrtA-mediated surface protein, as the bacterial surface binding partner for vWbp. Both vWbp and ClfA were shown to be crucial factors in the initial adhesion of S. aureus to the vascular endothelium.
S. aureus has many surface proteins that enable its binding to host proteins, endothelial cells or to subendothelial matrix. These surface proteins or MSCRAMMs (e.g. ClfA, FnBPA/B and SpA) are covalently bound to the cell wall by a transpeptidase, SrtA. Absence of SrtA leads to the defective anchoring of about 20 staphylococcal surface proteins [13] [14] [15] . Our findings indicate that the srtA gene and the subsequent correct anchoring of staphylococcal surface proteins are vital for S. aureus binding to the vascular endothelium via VWF. However, the adhesive contribution of these proteins in a flow field remains uncertain. Whereas the surface proteins ClfA and SpA can bind to vWbp, only ClfA contributed to the adhesion of S. aureus to the vascular endothelium via VWF in flow. ClfA is known to adhere to endothelial cells via fibrinogen and fibronectin, but it has never been associated with VWF binding. SpA binding to VWF has been reported in static conditions; however, in flow, the recruitment of S. aureus to endothelial cells is SpA independent [5, 6] . VWF circulates in a compact globular form, but is progressively unfolded in a flow field or when bound to collagen, thereby exposing VWF A1, A2 and A3-domain [7] . It has been described that bacteria can bind to endothelial cells via VWF [5, 6, 31] . Similar to our findings, Pappelbaum et al. showed that ADAMTS-13 decreased VWFmediated S. aureus adhesion to endothelial cells by 50% [5] . We have previously shown that binding of S. aureus to VWF can be blocked by an A1 neutralizing antibody, an antibody that also blocks the binding of platelets to VWF [6] . We now show that S. aureus binds directly to the VWF A1-domain and does so via vWbp and ClfA.
L. lactis, non-pathogenic bacteria, process their surface proteins in a similar way to S. aureus via a LPXTG motif. L. lactis expressing single staphylococcal surface molecules on their cell walls are therefore widely used to study the adhesive properties of a single surface protein.
In 2013, Veloso et al. demonstrated the relevance of these lactococci expressing single surface proteins using a lowgrade bacteremia model [11, 20, 32] . Using an L. lactis strain expressing ClfA, we confirmed that the simple presence of ClfA was sufficient to confer adhesion to the VWF A1-domain, but only in the presence of vWbp.
S. aureus exploits a variety of mechanisms to interact with and bind to the host's tissue. Therefore, targeting a single virulence factor may be insufficient to block clinically relevant bacterial adhesion. We confirmed the pathophysiological relevance of this adhesion mechanism by studying in vivo adhesion of S. aureus to the murine mesenteric circulation. Indeed, S. aureus binding to activated endothelium in vivo was also VWF, vWbp and ClfA dependent. Adding vWbp restored the adhesive phenotype of the vWbp mutant strain, again highlighting the importance of this protein in bacterial adhesion to the vessel wall. As absence of either ClfA or vWbp prevented bacterial adhesion in vivo, it is tempting to speculate about the therapeutic potential of a strategy targeting these factors in patients with S. aureus bacteremia [33] [34] [35] . Interestingly, it was previously shown that a vaccine strategy against ClfA reduced the incidence of experimental infective endocarditis in bacteremic mice [34] . Similarly, vaccinating against ClfA also reduced binding of S. aureus to an aortic patch in mice [29] .
In summary, our work identifies ClfA as a novel bacterial binding partner for staphylococcal vWbp. Together, these two proteins promote the adhesion of S. aureus to vascular endothelium. Further unraveling of the interactions between VWF, secreted vWbp and bacterial ClfA may lead to novel preventive or therapeutic strategies that reduce the high mortality of S. aureus infective endocarditis. designed the research, contributed vital new agents, and contributed to writing the manuscript.
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Additional Supporting Information may be found in the online version of this article: Fig. S1 . Micro-parallel flow chamber perfusion over coated collagen (200 lg mL À1 ) with fluorescently labeled wild-type (WT), vwb, srtA, clfA and spa strains at a shear rate of 1000 s À1 (n ≥ 6). Where indicated, 60 lg mL
À1
von Willebrand factor (VWF) was added to the perfusate. All results are expressed as mean AE SEM. Fig. S2 . Micro-parallel flow chamber perfusion over coated von Willebrand factor (VWF) (50 lg mL À1 ) with fluorescently labeled vwb and clfA strains at a shear rate of 1000 s À1 (n ≥ 6).
Video S1. Real-time adhesion of S. aureus Newman to activated vessel wall of wild-type (WT) mice. Video S2. Real-time adhesion of vwb to activated vessel wall of wild-type (WT) mice. Video S3. Real-time adhesion of vwb supplemented with 20 lg mL À1 rvWbp to activated vessel wall of wild-type (WT) mice.
